Prestige BioPharma invests its expertise and resources in the development of biosimilars and new first-in-class antibody therapeutics.
PBP’s current biosimilar portfolio includes:
PBP’s current first in class antibody therapeutics portfolio includes:
The first biosimilar of PBP, HD201 Trastuzumab, has been filed and accepted for review with the EMA, projecting market launch in 2021. Prestige BioPharma´s next products in line include a Bevacizumab biosimilar (HD204) in Phase III, an Adalimumab biosimilar (PBP1502) in Phase I, and an innovative anti-PAUF mAb (PBP1510) for the treatment of pancreatic cancer in Phase I stages. Manufacturing facilities for global commercial supply are located in Osong, South Korea.
Drug | Category | Indication |
---|---|---|
HD201 | Biosimilar, Trastuzumab (Herceptin) | Breast Cancer, Gastric Cancer |
HD204 | Biosimilar, Bevacizumab (Avastin) | Solid Tumors |
PBP1502 | Biosimilar, Adalimumab (Humira) | Arthritis |
PBP1510 | First In Class Antibody | Pancreatic Cancer |
PBP1601 | Biosimilar, Denosumab | Bone Loss, Osteoporosis |
PBP1602 | Biosimilar, Aflibercept | Macular Edema, Metastatic Colorectal Cancer, Retinopathy |
PBP1603 | Biosimilar, Eculizumab | Atypical Haemolytic Uremic Syndrome, Paraoxysmal Nocturnal Hemoglobinuria |
PBP1701 | Biosimilar, Ipilimumab | Metastatic Melanoma, Unresectable Melanoma |
PBP1710 | First In Class Antibody | Solid Tumors |
PBP1801 | Biosimilar, Pertuzumab (Perjeta) | Breast Cancer |